Company has initiated Phase 1 study with STRO-004, its potential best-in-class Tissue Factor ADC - - Sutro has selected PTK7 as the target for its initial dual-payload candidate, STRO-227 - - Investor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback